Hoʻemi ka GH / IGF-1 i ka physiologically me ka makahiki, a ua hui pū ʻia kēia mau hoʻololi me ka luhi, atrophy ʻiʻo, hoʻonui i ka adipose tissue, a me ka deterioration cognitive i ka poʻe ʻelemakule ...
I ka makahiki 1990, ua paʻi ʻo Rudman i kahi pepa ma ka New England Journal of Medicine i hoʻokūhoihoi i ke kaiāulu olakino - "The Use of Human Growth Hormone in People Over 60 Years of Age". Ua koho ʻo Rudman i 12 mau kāne 61-81 makahiki no nā hoʻokolohua lapaʻau:
Ma hope o 6 mau mahina o ka hGH injection, ua piʻi ka awelika o ka poʻe i ka 8.8% i ka nui o ka ʻiʻo, 14.4% i ka momona momona, 7.11% i ka mānoanoa o ka ʻili, 1.6% i ka iwi iwi, 19% i ka ate a me 17% i ka spleen i hoʻohālikelike ʻia me ka pūʻulu mana o nā poʻe kahiko o ka makahiki like. %.
Ua alakaʻi kēia hopena i ka hoʻolaha nui ʻana o ka recombinant human growth hormone (rhGH) ma ke ʻano he lāʻau kūʻē i ka wā kahiko, a ʻo ia hoʻi ke kumu kumu o ka manaʻo o ka poʻe he hiki ke hoʻopaʻa ʻia ka rhGH i ka wā kahiko. Mai ia manawa, nui nā kauka i hoʻohana i ka hGH ma ke ʻano he lāʻau anti-aging, ʻoiai ʻaʻole i ʻae ʻia e ka FDA.
Eia nō naʻe, i ka hoʻomau ʻana o ka noiʻi ʻana, ua ʻike nā ʻepekema ʻo nā pōmaikaʻi liʻiliʻi i ke kino o ka hoʻonui ʻana i ka hana o ka axis GH/IGF-1 ʻaʻole ia e hoʻolōʻihi i ke ola o ka poʻe ʻelemakule, akā ke kau nei i nā pilikia olakino:
ʻO nāʻiole oversecreting GH he nui, akā, he 30% -40% ka pōkole o ke ola ma mua o nāʻiole wild-type [2], a me nā loli histopathological (glomerulosclerosis a me ka hepatocyte proliferation) hiki i nāʻiole me nā kiʻekiʻe GH kiʻekiʻe. nui) a me ka pale ʻana i ka insulin.
ʻO nā kiʻekiʻe kiʻekiʻe o GH e hoʻoulu i ka ulu ʻana o nā ʻiʻo, nā iwi, a me nā ʻāpana o loko, e alakaʻi ana i ka gigantism (i nā keiki) a me ka acromegaly (i nā pākeke). Hoʻopili pinepine ʻia nā pākeke me ka nui o ka GH me ka maʻi maʻi a me nā pilikia puʻuwai, a me ka nui o ka maʻi kanesa.
Ka manawa hoʻouna: Iulai-22-2022